Mycobacterium vaccae nebulization protects Balb/c mice against bronchial asthma through neural mechanisms

• Published in: The Journal of asthma 2021-08, Vol.58 (8), p.1003-1012
• Main Authors: Jiang, Xiao-Hong, Li, Chao-Qian, Feng, Guang-Yi, Luo, Ming-Jie, Sun, Qi-Xiang, Huang, Jianlin
• Format: Article
• Language: English
• Subjects: Acetylcholine; brain-derived neurotropic factor; chronic airway inflammation; nerve growth factor; neurofilament; neurotrophic factor 3
• ISSN: 0277-0903; 1532-4303
• DOI: 10.1080/02770903.2020.1761381

Bronchial asthma can be effectively controlled but not be cured, its etiology and pathogenesis are still unclear, and there are no effective preventive measures. The key characteristic of asthma is chronic airway inflammation, and recent research has found that airway neurogenic inflammation plays an important role in asthma. We previously found that Mycobacterium vaccae nebulization protects against asthma. Therefore, this objective of this study is to explore the effect of M. vaccae nebulization on asthmatic neural mechanisms. A total 18 of female Balb/c mice were randomized into normal, asthma control, and M. vaccae nebulization (Neb.group) groups, and mice in the Neb.group were nebulized with M. vaccae one month before the asthmatic model was established. Then, 1 month later, the mice were sensitized and challenged with ovalbumin. Twenty-four hours after the last challenge, mouse airway responsiveness; pulmonary brain-derived neurotropic factor (BDNF), neurofilament-medium length (NF-M, using NF09 antibody), and acetylcholine expression; and nerve growth factor (NGF) mRNA level were determined. We found that the BDNF, NF09, acetylcholine expression, and NGF mRNA level were decreased in the Neb.group compared with levels in the asthma control group. M. vaccae nebulization may protected in Balb/c mice against bronchial asthma through neural mechanisms.